Article

Integrating Genetic Variants and Expression Profiles of Pharmacogenes in Treatment- Resistant Depression

2025-10-15

Abstract excerpt

<title>Abstract</title> <p>Background. Treatment-resistant depression (TRD) is a major clinical challenge in the management of major depressive disorder (MDD). While pharmacogenetics has been suggested to have some clinical utility in guiding antidepressant treatment, only few studies have explored if and how pharmacogenes can be involved in TRD pathophysiology and its clinical outcomes. In this study we explored...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9f6b46a8-34f1-5e30-9e9f-e64ad7d861aa
DOI: 10.21203/rs.3.rs-7758521/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Integrating Genetic Variants and Expression Profiles of Pharmacogenes in Treatment- Resistant DepressionDOI 10.21203/rs.3.rs-7758521/v1Read

Integrating Genetic Variants and Expression Profiles of Pharmacogenes to Investigate Resistance to Antidepressant Treatment.Semantic proximity Read

Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics.Semantic proximity Read

Understanding response to treatment in depression: Insights from the Pakistani DIVERGE studySemantic proximity Read

Pharmacogenetic studies: a tool to improve antidepressant therapy.Semantic proximity Read

Rates of Divergent Pharmacogenes in a Psychiatric Cohort of Inpatients with Depression—Arguments for Preemptive TestingSemantic proximity Read

Pharmacogenomic profiling of CYP2D6 and CYP2C19 in Indian psychiatric patientsSemantic proximity Read

Study protocol for an observational trial: Investigating pharmacogenetic impact on depression treatment using various sequencing and array methods (PharmGen-TRD Study)Semantic proximity Read

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and FutureSemantic proximity Read

Role of the Pharmacogenomics in the Treatment-Resistant Depression: A Literature ReviewSemantic proximity Read

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Semantic proximity Read

Depression and Pharmacogenetics.Semantic proximity Read

A naturalistic retrospective evaluation of the utility of pharmacogenetic testing based on CYP2D6 e CYP2C19 profiling in antidepressants treatment in a cohort of patients with major depressive disorder.Semantic proximity Read